Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma

Published:2016-05-27 Issue:5 Volume:11 Page:e0156369
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Brown Nicholas,McBain Catherine,Nash Stephen,Hopkins Kirsten,Sanghera Paul,Saran Frank,Phillips Mark,Dungey Fiona,Clifton-Hadley Laura,Wanek Katharina,Krell Daniel,Jeffries Sarah,Khan Iftekhar,Smith Paul,Mulholland Paul

Funder

AstraZeneca (GB)

Cancer Research UK

NIHR/Wellcome UCH Clinical Research Facility

UCH/UCL Biomedical Research Centre and UCL Experimental Cancer Medicine Centre

National Brain Appeal

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. Glioblastoma in England: 2007–2011;A Brodbelt;Eur J Cancer,2015

2. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012;QT Ostrom;Neuro-oncology,2015

3. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;R Stupp;The New England journal of medicine,2005

4. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;R Stupp;The Lancet Oncology,2009

5. EGFR and cancer prognosis;RI Nicholson;Eur J Cancer,2001

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials;Cancers;2024-08-29

2. “Transcriptomic Profiling Unveils Novel Therapeutic Options for Drug-Resistant Temporal Lobe Epilepsy”;2024-06-26

3. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment;Critical Reviews in Oncology/Hematology;2024-06

4. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives;Journal of Hematology & Oncology;2024-05-08

5. Glioblastoma Therapy: Past, Present and Future;International Journal of Molecular Sciences;2024-02-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3